Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines - Takeaways - MDSpire

Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines

  • By

  • Laura M King

  • Kristin L Andrejko

  • Miwako Kobayashi

  • Wei Xing

  • Adam L Cohen

  • Wesley H Self

  • J Jackson Resser

  • Cynthia G Whitney

  • Adrienne Baughman

  • Mai Kio

  • Carlos G Grijalva

  • Jessica Traenkner

  • Nadine Rouphael

  • Joseph A Lewnard

  • July 22, 2025

  • 0 min

Share

  • 1

    Next-generation pneumococcal conjugate vaccines (PCVs) target a growing range of serotype antigens to combat invasive pneumococcal disease (IPD) and acute respiratory infections (ARIs).

  • 2

    In children, the proportion of pneumococcal acute otitis media (AOM) cases attributable to PCV31 serotypes is 68%, while in adults, PCV31 covers 87% of nonbacteremic pneumonia cases.

  • 3

    Annual preventable burdens by PCVs include 270,000 to 3.3 million outpatient-managed ARIs and 3,000 to 14,000 IPD cases in the United States.

  • 4

    PCV15 shows the lowest coverage for preventable burdens, while PCV31 demonstrates the highest coverage, indicating significant differences in vaccine effectiveness.

  • 5

    The study utilized Markov chain Monte Carlo methods to estimate serotype distributions and potential vaccine-preventable disease burdens in US children and adults.

Original Source(s)

Related Content